FENC
Next earnings: Aug 13, 2026 · Before open
Signal
Leaning Bullish21
Price
1
Move+5.52%Strong session
Volume
1
Volume2.8× avgSurge — unusual activity
Technical
1
RSIRSI 34Momentum negative
PRICE
Prev Close
9.24
Open
9.44
Day Range9.17 – 10.17
9.17
10.17
52W Range5.65 – 10.17
5.65
10.17
91% of range
VOLUME & SIZE
Avg Volume
216.6K
FUNDAMENTALS
P/E Ratio
-33.6x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
0.37
Low vol
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +65% YoY · 92% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 7.0 · FCF negative
Bullish
Key MetricsTTM
Market Cap$278.66M
Revenue TTM$51.00M
Net Income TTM-$8.38M
Free Cash Flow-$5.78M
Gross Margin92.2%
Net Margin-16.4%
Operating Margin-11.0%
Return on Equity-55.1%
Return on Assets-11.7%
Debt / Equity0.00
Current Ratio6.98
EPS TTM$-0.24

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
50/100
Liquidity
6.98Strong
Leverage
0.00Strong
Coverage
-3.7xConcern
ROE
-55.1%Concern
ROIC
-9.0%Concern
Cash
$37MStrong
ANALYST COVERAGE7 analysts
BUY
+84.6%upside to target
Buy
7100%
7 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
Stock Health
Composite Score
4 of 5 signals bullish
8/10
Technicals
RSI RangeRSI 34 — Bearish momentum
Volume
Volume FlowAccumulation — institutional buying
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 6.98 — healthy liquidity
Upcoming Events
EEarnings ReportMay 18, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 89 days
PDividend PaymentAug 28, 2026
In 103 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

UptrendDeath Cross · 50D trails 200D by 4.7%

+24.5% vs SMA 50 · +18.6% vs SMA 200

Momentum

RSI33.6
Momentum fading
MACD-0.14
Below zero — bearish pulse · expanding
Market Position
Price Levels
52W High
$10.17+4.3%
Current
$9.75
EMA 200
$8.13-16.6%
EMA 50
$7.75-20.6%
52W Low
$5.65-42.1%
52-Week RangeNear 52-week high
$5.6591th %ile$10.17
Squeeze SetupVolume-based
Elevated Squeeze Setup

Strong accumulation on above-average volume. Buyers are absorbing supply aggressively — any positive catalyst could trigger a rapid covering move.

20-Day Money Flow
Acc days:3
Dist days:0
Edge:+3 acc
Volume Context
Avg Vol (50D)235K
Recent Vol (5D)
655K+178%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 5 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$45.6M
$44.5M$46.5M
-$0.13
±30%
High5
FY2026(current)
$68.7M
$65.8M$75.3M
+50.6%$0.27
±40%
Moderate4
FY2027
$102.4M
$99.4M$106.5M
+49.1%$1.00+266.5%
±34%
High5
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryFENC
Last 8Q
-108.0%avg beat
Beat 3 of 8 quartersMissed 5 Estimates falling
-433%
Q3'24
-62%
Q4'24
-111%
Q1'25
+67%
Q2'25
-83%
Q3'25
+75%
Q4'25
-467%
Q1'26
+150%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
Cantor FitzgeraldOverweight
Nov 22
UPGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $129K sold · 30d window
Rallis Chris ADir
$59K
May 11
SELL
Raykov RostyDir
$70K
May 1
SELL
Raykov RostyDir
$69K
Apr 1
SELL
Raykov RostyDir
$84K
Mar 2
SELL
Raykov RostyDir
$80K
Feb 2
SELL
Raykov RostyDir
$78K
Jan 2
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
Rosalind Advisors, Inc.
2.9M
2
Southpoint Capital Advisors LP
2.7M
3
Solas Capital Management, LLC
2.5M
4
AIGH Capital Management LLC
2.0M
5
BlackRock, Inc.
1.4M
6
AWM Investment Company, Inc.
720K
7
GEODE CAPITAL MANAGEMENT, LLC
372K
8
STATE STREET CORP
359K
News & Activity

FENC News

About

fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Rostislav Raykov
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
FENC
$9.75+0.00%$279M-2182.0%1500
$66.13-5.07%$13.0B+12626.1%-14525.8%1500
$94.92-3.79%$12.6B+3288.2%-4239.0%1500
$523.69-3.00%$12.1B+43205.3%-3008.0%1500
$227.72-1.96%$11.7B+6554.5%-2868.8%1500
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
$76.67-3.79%$10.8B+2325815.3%-19.7%1500
Sector avg-2.64%50.3+398824.8%-3813.6%1500